A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD

Inclusion Criteria: * Subjects with a clinically documented history of COPD for at least 1 year in accordance with the definition by the American Thoracic Society/European Respiratory Society. * Subjects must present with the following: a measured pre and post-salbutamol Forced expiratory volume in one second/ Forced vital capacity (FEV1/FVC) ratio of \<0.70 to confirm the diagnosis of COPD; a measured post-salbutamol FEV1\>20% and ≤80% of predicted normal values * Baseline mMRC dyspnea score 1 to 3 * Post-bronchodilator FEV1 \> 50% predicted (GOLD COPD grade 1-2) * Smoking pack years ≥ 10 years * Age ≥ 40 years * Acceptable standard-of-care COPD maintenance therapy includes long-acting beta-agonists (LABAs), long-acting muscarinic antagonists (LAMAs), inhaled corticosteroids (ICS), or combinations thereof (e.g., dual LABA/LAMA, or triple LABA/LAMA/ICS therapy). The patient must have been on a stable dose and regimen for at least 4 weeks prior to screening with no changes anticipated during the study unless medically necessary. * A history of ≥ 1 exacerbations in the last 12 months * Be able to provide written consent; compliant with study procedures and study visits. Exclusion Criteria: * Patients whose treatment is considered palliative (life expectancy \<12 months) Comorbid severe lung disease, such as bronchiectasis, pulmonary fibrosis * Current smoker or cessation within 3 months of screening, or current use of vaping device * Patients with pneumonia or COPD exacerbat…